Rituximab in ANCA-associated vasculitis: a revolution?

被引：14
|
作者：
Tervaert, Jan Willem Cohen [1 ]
机构：
[1] Maastricht Univ Med Ctr, Dept Internal Med, Div Clin & Expt Immunol, Maastricht, Netherlands
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2011年 / 26卷 / 10期
关键词：
ANCA; pathophysiology; rituximab; therapy; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; WEGENERS-GRANULOMATOSIS; SYSTEMIC VASCULITIS; RENAL VASCULITIS; ANIMAL-MODEL; GLOMERULONEPHRITIS; CYCLOPHOSPHAMIDE; AAV; RTX; ACTIVATION;
D O I：
10.1093/ndt/gfr507
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：3077 / 3079
页数：3
相关论文
共 50 条
  • [31] Rituximab and B-Cell Return in ANCA-Associated Vasculitis
    Wilde, Benjamin
    Witzke, Oliver
    Tervaert, Jan Willem Cohen
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (06) : 1066 - 1066
  • [32] Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement
    Geetha, Duvuru
    Specks, Ulrich
    Stone, John H.
    Merkel, Peter A.
    Seo, Philip
    Spiera, Robert
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    St Clair, E. William
    Fessler, Barri J.
    Ding, Linna
    Tchao, Nadia K.
    Ikle, David
    Jepson, Brett
    Brunetta, Paul
    Fervenza, Fernando C.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (04): : 976 - 985
  • [33] Rituximab versus azathioprine for maintenance therapy in ANCA-associated vasculitis
    Clark, Anna
    LANCET RHEUMATOLOGY, 2020, 2 (01): : E12 - E12
  • [34] Successful treatment of ANCA-associated vasculitis and CNS involvement with rituximab
    Zeglam, S.
    Werthmann, M.
    Scheicht, D.
    Bansmann, P.
    Strunk, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 145 - 145
  • [35] Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis
    Cornec, Divi
    Kabat, Brian
    Mills, John
    Cheu, Melissa
    Hummel, Amber
    Schroeder, Darrell
    Cascino, Matthew
    Brunetta, Paul
    Murray, David
    Snyder, Melissa
    Fervenza, Fernando
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    Langford, Carol A.
    Merkel, Peter A.
    Monach, Paul A.
    Seo, Philip
    Spiera, Robert F.
    St Clair, E. William
    Stone, John H.
    Barnidge, David
    Specks, Ulrich
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [36] Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis
    van Daalen, Emma E.
    Rizzo, Raffaella
    Kronbichler, Andreas
    Wolterbeek, Ron
    Bruijn, Jan A.
    Jayne, David R.
    Bajema, Ingeborg M.
    Rahmattulla, Chinar
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 1064 - 1069
  • [37] Rituximab for remission induction in elderly patients with ANCA-associated vasculitis
    Timlin, H.
    Lee, S. M.
    Manno, R. L.
    Seo, P.
    Geetha, Duvura
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 45 (01) : 67 - 69
  • [38] SEVERE INFECTIONS IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS TREATED WITH RITUXIMAB
    Segelmark, Leo
    Felipe Flores-Suarez, Luis
    Rathmann, Jens
    Mohammad, Aladdin
    RHEUMATOLOGY, 2019, 58
  • [39] Acquired hemophilia in association with ANCA-associated vasculitis: Response to rituximab
    Clatworthy, MR
    Jayne, DRW
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : 680 - 682
  • [40] Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
    Jones, Rachel B.
    Tervaert, Jan Willem Cohen
    Hauser, Thomas
    Luqmani, Raashid
    Morgan, Matthew D.
    Peh, Chen Au
    Savage, Caroline O.
    Segelmark, Marten
    Tesar, Vladimir
    van Paassen, Pieter
    Walsh, Dorothy
    Walsh, Michael
    Westman, Kerstin
    Jayne, David R. W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03): : 211 - 220
12345